Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/03/2022* -- Results Q2 2022 -- -2.17 --
08/03/2022* 08:00 EST Earnings Call Q2 2022 -- -- --
05/03/2022 -- Results Q1 2022 -2.07 -2.00 -3.75%
05/03/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/24/2022 -- Results Q4 2021 -2.12 -2.16 2.00%
02/24/2022 08:00 EST Earnings Call Q4 2021 -- -- --
11/02/2021 -- Results Q3 2021 -2.21 -1.86 -18.78%
11/02/2021 08:00 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 08/03/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/03/2022
Beat/Miss Upgrade
Return Since -0.79%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development.
URL http://www.sagerx.com
Investor Relations URL https://investor.sagerx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Aug. 03, 2022 (est.)
Last Earnings Release May. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
59.29%
-12.42%
222.6%
-41.84%
-24.64%
19.84%
-50.83%
-23.53%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.67%
-9.75%
-7.43%
21.96%
-5.54%
-1.39%
-17.48%
-2.02%
-16.78%
-42.06%
-35.72%
37.00%
-19.35%
3.56%
-9.26%
-24.14%
-35.81%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
4.69%
--
--
--
--
28.09%
434.1%
143.1%
-46.35%
As of May 20, 2022.

Profile

Edit
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development.
URL http://www.sagerx.com
Investor Relations URL https://investor.sagerx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Aug. 03, 2022 (est.)
Last Earnings Release May. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
SMHCLX 507.00 USD 5.07%
AGF489 9.622M USD 2.81%
SMHCJX 246.00 USD 2.46%
NIFE 77633.00 USD 2.40%
BBP 272048.0 USD 2.03%
SBIO 1.820M USD 1.90%
XBI 65.49M USD 1.15%
LABU 4.362M USD 0.64%
EES 3.576M USD 0.62%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter SAGE Tweets